trial · primary record
Soquelitinib
Autoimmune Lymphoproliferative Syndrome
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2026-12-01 |
| Primary endpoint | Reduction of spleen volume or target lymph node volume by 25% from baseline to day 90, assessed by CT or PET/CT scan. |
| Registry ID | NCT06730126 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:43.284Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06730126
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.